Zevra Therapeutics (NASDAQ:ZVRA) Rating Lowered to “Hold” at Wall Street Zen

Zevra Therapeutics (NASDAQ:ZVRA) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Saturday.

Other analysts have also issued reports about the company. Guggenheim boosted their target price on Zevra Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Weiss Ratings lowered Zevra Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research note on Friday, May 22nd. Finally, BTIG Research started coverage on Zevra Therapeutics in a research note on Monday, March 16th. They issued a “buy” rating and a $23.00 target price on the stock. Seven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $23.33.

Zevra Therapeutics Trading Down 5.0%

ZVRA stock opened at $10.61 on Friday. The stock’s fifty day simple moving average is $10.32 and its two-hundred day simple moving average is $9.37. Zevra Therapeutics has a 1-year low of $7.16 and a 1-year high of $13.16. The stock has a market cap of $627.26 million, a P/E ratio of 5.33 and a beta of 0.91.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its earnings results on Wednesday, May 6th. The company reported $0.18 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.12. The firm had revenue of $36.22 million for the quarter, compared to analyst estimates of $31.96 million. Zevra Therapeutics had a return on equity of 51.49% and a net margin of 101.58%. As a group, analysts forecast that Zevra Therapeutics will post 0.56 earnings per share for the current fiscal year.

Institutional Trading of Zevra Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Gunpowder Capital Management LLC dba Oliver Wealth Management bought a new stake in shares of Zevra Therapeutics during the 4th quarter valued at $53,000. Russell Investments Group Ltd. raised its stake in shares of Zevra Therapeutics by 235.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock valued at $61,000 after purchasing an additional 4,475 shares during the period. Tower Research Capital LLC TRC raised its stake in shares of Zevra Therapeutics by 617.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock valued at $88,000 after purchasing an additional 8,552 shares during the period. Creative Planning bought a new stake in shares of Zevra Therapeutics during the 2nd quarter valued at $92,000. Finally, Qube Research & Technologies Ltd bought a new stake in shares of Zevra Therapeutics during the 2nd quarter valued at $99,000. 35.03% of the stock is currently owned by institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.